What does science say about Fasting and fasting-mimicking diet and Ulcerative colitis?
- We don’t say yes or no. We show what has been studied.
- Working in a lab or in animals does not mean it works in people.
- Don’t stop or change your treatment without talking to your doctor.
What has been studied
- Lab studies (cells)Tests on cells in a dish.Source: PubMed · as of 6 Nov 2026 · Open the search at PubMed0studies
- Animal studiesTests in mice, rats or other animals.Source: PubMed · as of 6 Nov 2026 · Open the search at PubMed3studies
- Studies in peoplePublished studies with human participants.Source: PubMed · as of 6 Nov 2026 · Open the search at PubMed11studies
- Registered trials in peopleTrials entered in a public registry, whatever their result.ClinicalTrials.gov: 4 · as of 6 Nov 2026 · Open the search at ClinicalTrials.govEU CTIS: 5 · as of 6 Nov 2026 · Open the search at EU CTISBy phase:Phase 1 (5)No phase (3)Phase 3 (1)By status:Completed (6)Recruiting (2)Not yet recruiting (1)Countries (3):Romania (5)Canada (2)United States (2)With a linked publication (results): 0 of 9The registries do not tell us here whether results were posted; a linked publication is shown instead.9trials
- Approved treatmentApproved by a medicines regulator for this disease.No
Examples of what we found
The trials
Phase 1
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.
Recruiting · Romania
EU CTIS · 2026-525798-38-00Phase 1
A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.
Not yet recruiting · Romania
EU CTIS · 2025-522106-20-00No phase
The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
Recruiting · United States
ClinicalTrials.gov · NCT03615690Phase 1
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.
Completed · Romania
EU CTIS · 2025-520617-31-00Phase 1
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
Completed · Romania
EU CTIS · 2024-512770-10-00Phase 1
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
Completed · Romania
EU CTIS · 2024-512773-27-00No phase
Fasting-mimicking Diet in Treatment of Depressive Symptoms in IBD
Completed · Canada
ClinicalTrials.gov · NCT05382897Phase 3
Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis
Completed · United States
ClinicalTrials.gov · NCT04505410
Thinking of paying for it? Read this first
- Ask for published results. Stories, thank-you letters and "patients report" are not results. Ask where the results were published.
- Know what you pay for. Ask in writing: what exactly is included, who gets the money, and what happens if you stop.
- Ask your own doctor first. Some products interfere with chemotherapy, radiation or other medicines. Your treating doctor can check this.
- Do not stop standard treatment for it. Do not stop or delay your treatment without talking to your care team.
Other treatments people ask about
- Cannabis and cannabinoids (CBD, THC)Step: Large trials
- Curcumin (turmeric)Step: Large trials
- Fasting and fasting-mimicking dietStep: Large trials
- High-dose vitamin CStep: Large trials
- MebendazoleStep: Large trials
- MelatoninStep: Large trials
- MetforminStep: Large trials
- StatinsStep: Large trials
- Vitamin DStep: Large trials
- HyperthermiaStep: Reports in people
- Ketogenic dietStep: Reports in people
- Mistletoe extractStep: Reports in people
- Dichloroacetate (DCA)Step: Animal studies only
Not medical advice. Talk to the care team before changing treatment.